Metall + Plastic joins Optima Group
Pharmaceutical filling and closing is united with isolator technology
Optima Group Pharma, a leading manufacturer of filling and packaging lines, says the product portfolios of both companies ideally complement each other and the addition of Metall + Plastic’s products completes its portfolio.
Manufacturing at the Metall + Plastic headquarters will continue unchanged and Christoph von Stenglin remains as managing director.
Optima Group says the driving motivation for the acquisition was the ability to bring turnkey solutions to market. The Group now offers a comprehensive range of equipment, including filling and closing systems, pharmaceutical lyophilisation, e-beam sterilisation and barrier technologies (including isolators).
Optima Group Pharma is a subsidiary of the Optima Group, which reported a turnover of €200m in 2009. The Group currently employs 1,200 people and expects further growth in 2011.
You may also like
Manufacturing
Technical rundown: new isolator technology for aseptic processes
Read moreAs the trends in pharmaceuticals progress they require new ideal conditions. A new design for isolator technology, Metall+Plastic’s INTISO, is distinguished by the absence of a HVAC unit and the relocation of cooling and ventilation units from the mechanical floor to the isolator plenum. This can create the ideal conditions for the biotechnology of the day; inactivated vaccines or insulin
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Technical rundown: new isolator technology for aseptic processes
As the trends in pharmaceuticals progress they require new ideal conditions. A new design for isolator technology, Metall+Plastic’s INTISO, is distinguished by the absence of a HVAC unit and the relocation of cooling and ventilation units from the mechanical floor to the isolator plenum. This can create the ideal conditions for the biotechnology of the day; inactivated vaccines or insulin